You are here
Study Evaluating the Safety and Tolerability of NSA-789
About this Study
This is the first time that NSA-789, a new compound being developed for schizophrenia, will
be given to humans. Each healthy subject will receive a single dose, except for 8 subjects
who will receive 2 doses-- one dose under fasting conditions and one dose after eating food.